Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALFENTA vs ACTICLATE CAP
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing c AMP production, leading to reduced neuronal excitability and pain transmission.
Inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking aminoacyl-t RNA binding.
Induction and maintenance of anesthesia,Analgesic supplement during surgical procedures,Intravenous use for monitored anesthesia care (MAC)
Treatment of infections caused by susceptible bacteria, including respiratory tract infections, urinary tract infections, and acne vulgaris
Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.
350 mg orally once daily, increased to 350 mg twice daily if no response after 2 weeks.
Terminal elimination half-life: 90–111 minutes (1.5–1.85 hours); prolonged in hepatic impairment.
Terminal elimination half-life 6-10 hours; prolonged in renal impairment (up to 22 hours in anuria)
Hepatic via CYP3A4 to inactive metabolites; major metabolite is desmethylalfentanil (inactive).
Primarily hepatic; metabolites include 4-epimino derivatives; not significantly metabolized via CYP450.
Primarily renal (urinary) elimination as metabolites; approximately 80% recovered in urine, 20% in feces.
Renal (60-70% as unchanged drug), fecal (20-30% as metabolites); minor biliary elimination
Approximately 92% bound, primarily to alpha-1 acid glycoprotein and albumin.
90-95% bound to serum proteins, primarily albumin
0.5–1.0 L/kg; reflects moderate tissue distribution; higher Vd in neonates and elderly.
0.75 L/kg (50-70 L in adults); distributes well into tissues including bone, teeth, and synovial fluid
Intravenous: 100%; intramuscular: approximately 90%; intrathecal: approximately 10% (due to systemic absorption following spinal administration).
Oral: 90-100% (capsule); food or dairy reduces absorption by up to 50%
No specific dose adjustment is recommended for renal impairment; however, alfentanil is primarily metabolized in the liver and its pharmacokinetics are not significantly altered in renal failure.
e GFR 30-59 m L/min: 350 mg once daily; e GFR <30 m L/min: not recommended.
In hepatic impairment (Child-Pugh class A, B, C): Reduce dose by 50% and titrate carefully due to prolonged elimination half-life. Consider lower initial doses and extended dosing intervals.
Child-Pugh A: no adjustment; Child-Pugh B or C: 175 mg once daily.
Children (1-12 years): Induction of anesthesia: 10-20 mcg/kg IV; maintenance: 5-10 mcg/kg IV or infusion 0.5-1 mcg/kg/min. For neonates and infants: Dose individualization required; titrate to effect.
Not established for children <12 years; for ≥12 years, same as adult dosing.
Elderly patients (>65 years): Reduce initial dose by 30-50% and administer slowly. Due to decreased clearance and increased sensitivity, lower infusion rates (e.g., 0.3-0.5 mcg/kg/min) may be needed.
Initiate at 175 mg once daily; titrate cautiously based on renal function.
Risk of respiratory depression, particularly in elderly or debilitated patients. Concomitant use with benzodiazepines or other CNS depressants may cause profound sedation, respiratory depression, coma, and death.
Photosensitivity: severe sunburn can occur with sun exposure; discontinue if photosensitivity occurs. Tooth development: use during tooth development (last half of pregnancy, infancy, childhood to age 8) may cause permanent tooth discoloration. Bone growth: may retard bone growth in premature infants. Renal toxicity: may cause azotemia, hyperphosphatemia, and acidosis. Avoid in renal impairment.
Respiratory depression; abuse potential; hypotension; bradycardia; muscle rigidity; serotonin syndrome with concurrent serotonergic drugs; adrenal insufficiency; risk of withdrawal with prolonged use.
Photosensitivity, tooth discoloration, bone growth retardation, renal impairment, hepatotoxicity, increased intracranial pressure, superinfection, and use in pregnancy/lactation.
Hypersensitivity to alfentanil or any component; significant respiratory insufficiency; severe asthma; paralytic ileus; concurrent use of MAOIs (or within 14 days); acute or postoperative pain management in children (except for procedural sedation).
Hypersensitivity to tetracyclines, pregnancy, breastfeeding, children under 8 years, renal impairment, and concurrent use with oral retinoids.
No known interactions with food. However, grapefruit juice may increase alfentanil serum concentrations due to CYP3A4 inhibition; avoid concurrent consumption.
Avoid food and beverages for at least 1 hour before and after administration, as they can reduce the efficacy of activated charcoal. Do not mix with milk or ice cream, as they decrease binding capacity. Administer with water or a non-carbonated, non-alcoholic drink.
Alfentanil, a short-acting opioid analgesic, is classified as FDA Pregnancy Category C. No well-controlled studies in pregnant women exist. In animal studies, no teratogenic effects were observed at clinically relevant doses; however, high doses caused embryotoxicity and increased fetal mortality. Trimester-specific risks: First trimester - potential for minor malformations based on limited human data; second trimester - possible risk if used chronically; third trimester - prolonged use may lead to neonatal respiratory depression, withdrawal syndrome, or opioid dependence. Use only if benefits outweigh risks.
First trimester: Category D; tetracyclines can cause fetal harm including inhibited bone growth and discoloration of teeth (yellow-gray-brown). Second and third trimesters: Known to cause permanent tooth discoloration (enamel hypoplasia) and reversible inhibition of bone growth; use contraindicated after 15 weeks gestation.
Alfentanil is excreted into human breast milk in low concentrations. The milk-to-plasma (M/P) ratio is approximately 0.3. Estimated infant dose is <1% of maternal weight-adjusted dose, which is considered clinically insignificant. However, due to potential for neonatal opioid effects, caution is advised; monitor infant for drowsiness, respiratory depression, and feeding difficulties. Consider alternative analgesics with established safety profiles, such as acetaminophen or ibuprofen, for lactation.
Tetracyclines are excreted in breast milk but absorption by the infant is limited due to chelation with milk calcium; M/P ratio for doxycycline is approximately 0.3-0.4. Theoretical risk of tooth staining and bone inhibition, but clinical significance is low with short-term use; caution with prolonged therapy.
Pregnancy can alter pharmacokinetics of alfentanil. Increased plasma volume and distribution may require higher doses to achieve same effect, while decreased plasma protein binding may increase free fraction, potentiating effects. Alpha-1-acid glycoprotein levels change in pregnancy, affecting binding. In third trimester, clearance may be increased by up to 50% due to enhanced hepatic metabolism. Therefore, dose adjustments may be needed: consider starting at low dose and titrating to effect, with close monitoring. For intravenous administration, typical adult doses (5-20 μg/kg) may need adjustments; no standard pregnancy-specific dosing exists. Use the lowest effective dose for the shortest duration. In labor, avoid high doses prior to delivery due to risk of neonatal respiratory depression.
No dosage adjustment is typically recommended for doxycycline in pregnancy due to minimal pharmacokinetic changes; however, use is generally avoided in the second and third trimesters. If indicated, standard dosing may be used in the first trimester with caution.
Alfentanil is a potent, rapid-onset, short-acting opioid analgesic used primarily for induction and maintenance of anesthesia. Due to its high protein binding (90%) and rapid redistribution, it has a shorter duration of action than fentanyl, making it suitable for brief, painful procedures. It undergoes hepatic metabolism via CYP3A4, so concomitant use with CYP3A4 inhibitors like ketoconazole or erythromycin can prolong its effects. Use caution in elderly or hypovolemic patients due to increased risk of hypotension. Naloxone reverses respiratory depression. Alfentanil is 5-10 times less potent than fentanyl.
ACTICLATE CAP is a high-dose activated charcoal formulation used for acute poisoning or overdose. Administer within 1 hour of ingestion for optimal efficacy. Do not use in patients with impaired consciousness unless the airway is protected. Monitor for vomiting and ensure rapid administration via nasogastric tube if necessary. Not effective for alcohols, metals, or caustics.
This medication is given only by a healthcare professional in a hospital or surgical setting.,You may feel drowsy, dizzy, or nauseated after receiving this drug.,Report any difficulty breathing or slow heart rate to your healthcare provider immediately.,Avoid alcohol and sedatives for 24 hours after administration, as they can increase side effects.,Do not drive or operate machinery until the effects have fully worn off.
Take ACTICLATE CAP only if directed by a healthcare professional after a poisoning or overdose.,This medication is not for regular use; it is a one-time emergency treatment.,Avoid taking this with food or drinks; take on an empty stomach for best absorption of toxins.,You may experience black stools or vomiting; this is normal.,Seek immediate medical attention if you have trouble swallowing, severe vomiting, or signs of bowel obstruction.
"Propantheline, an anticholinergic agent, can competitively antagonize muscarinic acetylcholine receptors, potentially reducing gastrointestinal motility and secretion. Alfentanil, a mu-opioid receptor agonist, also decreases gastrointestinal motility through central and peripheral opioid receptors. Concomitant use may synergistically inhibit peristalsis, leading to severe constipation, paralytic ileus, or delayed gastric emptying, which can increase the risk of aspiration and complicate anesthesia recovery."
"Alfentanil, a potent opioid analgesic, can cause significant hypotension and respiratory depression. When combined with furosemide, a loop diuretic that reduces blood volume and vascular resistance, there is a synergistic decrease in blood pressure, which may precipitate cardiovascular collapse, especially in patients with compromised circulatory reserves. Additionally, furosemide may enhance the sedative and respiratory depressant effects of alfentanil, leading to increased risk of respiratory acidosis and altered mental status."
"Alfentanil, a potent mu-opioid receptor agonist, can enhance the bradycardic effects of nebivolol, a beta-1 selective blocker with additional nitric oxide-mediated vasodilation. The combination may lead to excessive slowing of heart rate, reduced cardiac output, and potential hemodynamic instability, particularly in patients with underlying cardiac conduction abnormalities or hypovolemia."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALFENTA vs ACTICLATE CAP, answered by our medical review team.
ALFENTA is a Opioid Analgesic that works by μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing c AMP production, leading to reduced neuronal excitability and pain transmission.. ACTICLATE CAP is a Tetracycline Antibiotic that works by Inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking aminoacyl-t RNA binding.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALFENTA and ACTICLATE CAP depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALFENTA is: Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.. The standard adult dose of ACTICLATE CAP is: 350 mg orally once daily, increased to 350 mg twice daily if no response after 2 weeks.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALFENTA and ACTICLATE CAP in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALFENTA is classified as Category C. Alfentanil, a short-acting opioid analgesic, is classified as FDA Pregnancy Category C. No well-controlled studies in pregnant women exist. In animal studies, no teratogenic effect. ACTICLATE CAP is classified as Category C. First trimester: Category D; tetracyclines can cause fetal harm including inhibited bone growth and discoloration of teeth (yellow-gray-brown). Second and third trimesters: Known t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.